Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

(2017) Gustaaf W. van Imhoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

(2016) V Stefoni et al.   Blood Cancer Journal

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402

(2015) Thomas E. Witzig et al.   BRITISH JOURNAL OF HAEMATOLOGY

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

(2013) Jeffrey L. Vacirca et al.   ANNALS OF HEMATOLOGY

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

(2013) N. Mounier et al.   HAEMATOLOGICA

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

(2011) Francisco J. Hernandez-Ilizaliturri et al.   CANCER

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

(2011) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

(2010) P. L. Zinzani et al.   CLINICAL CANCER RESEARCH

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

(2009) Gaetano Corazzelli et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY